{
    "nctId": "NCT03394287",
    "briefTitle": "A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC",
    "officialTitle": "A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "ORR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients signed the written informed consent\n* Women aged 18-70.\n* The pathologic diagnosis of recurrent metastatic triple negative breast cancer \uff3bER-negative(IHC\\<1%), PR-negative(IHC\\<1%), HER2-negative\uff08IHC-/+ or IHC++ and FISH/CISH-\uff09\uff3d.\n* At least one measuring lesion that conforms to RECIST v1.1 standard.\n* The number of chemotherapy lines in the metastatic phase was \\<3 line.\n* Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1.\n* Have a life expectancy of at least 12 weeks.\n* Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment.\n* The patients can swallow pills.\n* The results of patients' blood tests are as follows: \u2022 Hb\u226590g/L; \u2022 Plt\u226590E+9/L; \u2022 Neutrophils\u22651.5E+9/L; \u2022 ALT and AST \u2264 triple of normal upper limit; \u2022 TBIL \u2264 1.5 times of normal upper limit; \u2022 Creatinine \u2264 1.5 times of normal upper limit.\n\nExclusion Criteria:\n\n* The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.\n* Subjects with severe allergic reactions to other monoclonal antibodies.\n* The subjects had a central nervous system metastases with clinical symptoms.\n* History of hypertension and antihypertensive medications are not well controlled.\n* A heart condition or disease that is not well controlled.\n* Subjects had active infections or recent treatment with a systemic immunostimulatory agent (received within the previous 4 weeks).\n* Other clinical trials of drugs were used in the first four weeks of the first medication.\n* Subjects with treatment history of anti-angiogenesis drugs or check-point inhibitors.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}